What is GHK-Cu? What the research actually shows

GHK-Cu is the copper-bound form of GHK, a three-amino-acid peptide that the body makes naturally. It is sold in skin creams and as an injectable "research" or compounded product.^[1][2] The human evidence is thin. There are two small old trials of topical products with mixed results, and no real human trial of injected GHK-Cu.^[3][4][2]

What it is

GHK is a peptide made of glycine, histidine and lysine. It is found in human plasma, saliva and urine. Reviews say its levels decline with age.^[1][2]

That last point is easy to misread. Because the body makes GHK, papers that simply measure its levels are not evidence that taking it works.^[1]

GHK-Cu is sold in two very different ways:

• As a cosmetic ingredient in skin creams and gels.^[2][5]
• As an injectable "research" or compounded product.^[2][5]

The human evidence is almost all from the skin-cream or gel side.^[2][5]

What human studies show

Here is what the human studies in our sources report:

• Diabetic foot ulcers (1994): a randomised, evaluator-blinded, placebo-controlled trial of a GHK-copper gel applied daily after debridement reported median ulcer-area closure of 98.5% versus 60.8% with vehicle (p < 0.05). The abstract does not give participant numbers. The trial is old, comes from the product's developers' era, and our records show no replication.^[4]
• After laser resurfacing (2006): in a randomised trial in which 13 patients finished, GHK-Cu skin-care products did not reduce redness or improve wrinkles or skin quality on objective measures. Patient questionnaires did show higher satisfaction with skin quality (p = 0.04).^[3]
• Scalp injections (2018): an open-label, single-arm pilot gave 1000 people scalp injections every 3 weeks for 8 sessions of a mix with six active ingredients, including copper tripeptide-1. 83% had less hair fall on a pull test. With no control group and six ingredients, this cannot show anything about GHK-Cu alone.^[6]
• Case report (2016): one 59-year-old man had a mixed cosmetic solution containing copper-GHK applied with a spray device weekly for 12 weeks. Wrinkles around the eye improved and no side effects were noted. This is one patient and a multi-ingredient product.^[7]

A 2026 systematic review calls the human literature thin and fragmented. It says most randomised trials are small and use facial cosmetic creams, and that microneedle delivery has not been tested in an adequately powered human RCT.^[2]

What animal and lab work shows

A large part of what is claimed for GHK-Cu comes from cell culture, animal work, and reviews written by the same small group of authors. The claims include wound repair, collagen and gene-expression changes.^[1][8][9]

Some examples:

• Mice aged 20-21 months were given GHK-Cu 15 mg/kg either intraperitoneally for 5 days or intranasally for 8 weeks. Intranasal dosing improved escape latency in a spatial task in both sexes. Intraperitoneal dosing gave only a transient improvement in males. This is a preprint, not peer-reviewed.^[10]
• In mice with DSS-induced colitis, GHK-Cu reduced weight loss and gut inflammation markers. The effect was tied to the SIRT1/STAT3 pathway. This is a mouse model plus cell culture.^[11]
• In zebrafish larvae, GHK-Cu reduced copper-sulphate- or LPS-induced inflammation. In worms it extended lifespan. Neither is a mammal.^[12][13]

Results like these can suggest ideas to test. They do not show the same effect in people.

Safety and legal status

Injection safety is poorly defined. FDA's category 2 page says compounded injectable GHK-Cu may carry immune-reaction risk from aggregation and impurities, and that there are limited human data to inform safety.^[14]

The small human studies reported no serious adverse effects. But they were short, small, or uncontrolled.^[3][6][7] Reviews of peptide use in sports medicine say rigorous human safety data are lacking for unapproved peptides including GHK-Cu.^[15][16]

On regulation, the picture has shifted a few times:

• On the FDA 503A list, updated 2026-05-14, GHK-Cu for non-injectable routes is back in Category 1 (under evaluation). It was removed on 2026-04-22 when its nominations were withdrawn, then added back after one nominator said on 2026-05-05 that it meant to withdraw only the injectable nomination.^[17]
• FDA intends to consult its compounding advisory committee about GHK-Cu before the end of February 2027.^[17]
• As of 2026-10-09, FDA's category 2 page lists GHK-Cu for injectable routes among nominated-but-withdrawn substances it had flagged for significant safety risk.^[14]
• A 2020-04-01 FDA warning letter to Tailor Made Compounding LLC listed GHK-Cu among bulk substances the firm compounded that were not eligible for the 503A exemptions.^[18]

The bottom line

GHK-Cu is a natural peptide with a lot of lab and animal interest, but little solid human proof. For topical use there are two small or old human trials with mixed results.^[3][4]

For injected GHK-Cu there is no randomised trial of it on its own. There is only a six-ingredient cosmetic mix and a one-person case report.^[2][6][7]

Long-term safety, copper exposure from repeated injection, and drug interactions are unstudied.^[14] Regulators have flagged injectable GHK-Cu for significant safety risk.^[14]